✦ LIBER ✦

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

✍ Scribed by Stephen A. Harrison; Will Fecht; Elizabeth M. Brunt; Brent A. Neuschwander-Tetri

Book ID: 102240998
Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 186 KB
Volume: 49
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.22575

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Orlistat for overweight subjects with no

Orlistat for overweight subjects with nonalcoholic steatohepatitis

✍ Joanna K. Dowman; Deborah Stocken; Jeremy W. Tomlinson; Philip Newsome 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 47 KB 👁 1 views

We read with interest the article by Harrison et al. 1 on the use of Orlistat in overweight patients with nonalcoholic steatohepatitis (NASH). Their prospective randomized trial of 41 patients concluded that improvement in liver histology was not significantly different after 36 weeks of treatment w

Orlistat for overweight subjects with no

Orlistat for overweight subjects with nonalcoholic steatohepatitis

✍ Teoman Dogru; Cemal Nuri Ercin; Ilker Tasci; Serkan Tapan; Zeki Yesilova; Ahmet 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 41 KB 👁 1 views

We read with great interest the article by Harrison et al. reporting the effect of Orlistat, an inhibitor of fat absorption, on the metabolic abnormalities, histopathologic findings, and cytokine levels in subjects with nonalcoholic steatohepatitis (NASH). 1 They showed that when compared to control

Ursodeoxycholic acid for treatment of no

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial

✍ Keith D. Lindor; Kris V. Kowdley; E. Jenny Heathcote; M. Edwyn Harrison; Roberta 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

No effective medical therapy is available for all patients with nonalcoholic steatohepatitis (NASH). Ursodeoxycholic acid (UDCA) has been suggested to be of benefit based on open label clinical studies. We randomized 166 patients with liver biopsy-proven NASH to receive between 13 and 15 mg/kg/d of

High-dose ursodeoxycholic acid therapy f

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

✍ Ulrich F. H. Leuschner; Birgit Lindenthal; Günter Herrmann; Joachim C. Arnold; M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 165 KB 👁 2 views

A phase 2, randomized, double-blind, pla

A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis

✍ Vlad Ratziu; Muhammad Y. Sheikh; Arun J. Sanyal; Joseph K. Lim; Hari Conjeevaram 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 356 KB

In nonalcoholic steatohepatitis (NASH), the extent of hepatocyte apoptosis correlates with disease severity. Reducing hepatocyte apoptosis with the selective caspase inhibitor GS-9450 has a potential for altering the course of the liver disease. In this phase 2, double-blind study, 124 subjects with

Rosiglitazone versus rosiglitazone and m

Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: A 12-month randomized, prospective, open- label trial

✍ Dawn M. Torres; Frances J. Jones; Janet C. Shaw; Christopher D. Williams; John A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB

Medication combinations that improve the efficacy of thiazolidinediones or ameliorate weight-gain side effects of therapy represent an attractive potential treatment for (NASH). The aim of this randomized, open-label trial was to assess the efficacy of rosiglitazone and metformin in combination vers